MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma

MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma

Abstract: In newly diagnosed multiple myeloma (NDMM), measurable residual disease (MRD) status is prognostically important, but its role in treatment decisions remains unclear. In a phase 2 trial, we assessed daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) induction followed by...

Full description

Saved in:

Bibliographic Details
Main Authors:	Manisha Bhutani, Myra Robinson, David Foureau, Shebli Atrash, Barry Paul, Fei Guo, Jason M. Grayson, Anna Ivanina-Foureau, Mauricio Pineda-Roman, Cindy Varga, Reed Friend, Christopher J. Ferreri, Xhevahire Begic, Sarah Norek, Tiffany Drennan, Michelle B. Anderson, James T. Symanowski, Peter M. Voorhees, Saad Z. Usmani
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	Blood Advances
Online Access:	http://www.sciencedirect.com/science/article/pii/S247395292400675X
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple Myeloma
by: Giuseppe Mele, et al.
Published: (2018-01-01)

Case of Stroke from Cerebral Vasculitis following Carfilzomib, Lenalidomide, and Dexamethasone Therapy in a Patient with Relapsing Multiple Myeloma
by: Deborah Osafehinti, et al.
Published: (2019-01-01)

Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham’s Lymphangiomatosis: Review of the Literature
by: Matthew Lee, et al.
Published: (2022-01-01)

Daratumumab for autoimmune diseases: a systematic review
by: Martin Krusche, et al.
Published: (2023-12-01)

Successful Control of Acute Myelofibrosis with Lenalidomide
by: G. Vassilopoulos, et al.
Published: (2010-01-01)

Identifying common pathways for doxorubicin and carfilzomib-induced cardiotoxicities: transcriptomic and epigenetic profiling
by: Conagh Kelly, et al.
Published: (2025-02-01)

Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy
by: Luciano J. Costa, et al.
Published: (2025-02-01)

Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
by: Davor Galusic, et al.
Published: (2025-01-01)

Bilateral Bulky Adrenal Plasmacytomas with Very Good Response to Daratumumab-Based Therapy
by: Fang-Yu Wang, et al.
Published: (2023-04-01)

Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL
by: Lavinia Arseni, et al.
Published: (2025-01-01)

Lenalidomide-Associated Immune Thrombocytopenia: A Case Report and Review of the Literature
by: William Forehand III, et al.
Published: (2020-01-01)

Lenalidomide and Dexamethasone for a Patient of POEMS Syndrome Presenting with Massive Ascites
by: Shuji Ueda, et al.
Published: (2014-01-01)

Acute Liver Rejection in a Multiple Myeloma Patient Treated with Lenalidomide
by: Iuliana Vaxman, et al.
Published: (2020-01-01)

The First Autopsy Case of Fatal Acute Cardiac Failure after Administration of Carfilzomib in a Patient with Multiple Myeloma
by: Teruhito Takakuwa, et al.
Published: (2019-01-01)

Daratumumab improves the hematological response and kidney function of patients with light chain deposition disease
by: Xin Zhang, et al.
Published: (2025-01-01)

Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin’s Lymphomas
by: Marco Gunnellini, et al.
Published: (2012-01-01)

Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review
by: Muhammad Husnain, et al.
Published: (2016-01-01)

A Case of Chemotherapy-Refractory “THRLBCL like Transformation of NLPHL” Successfully Treated with Lenalidomide
by: Mamatha Siricilla, et al.
Published: (2018-01-01)

Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries
by: Anas Hamad, et al.
Published: (2024-07-01)

Daratumumab for Bortezomib-Refractory Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits in Kidney Allograft: A Case Report
by: Zewei Chen, et al.
Published: (2025-02-01)

Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS
by: Thomas Cluzeau, et al.
Published: (2025-02-01)

A Case Report of Leptomeningeal Myelomatosis and Rapid Improvement with Regimen Consisting of Daratumumab, Pomalidomide, Vincristine, Procarbazine, and Dexamethasone
by: Jew Win Kuan, et al.
Published: (2022-01-01)

Salvage Therapy in Early Relapse of T-Lymphoblastic Leukemia/Lymphoma Using Daratumumab/Nelarabine Combination: Two Consecutive Cases
by: Ingolf Molle, et al.
Published: (2022-01-01)

The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma
by: R. Palmieri, et al.
Published: (2019-01-01)

Successful Use of Cyclophosphamide as an Add-On Therapy for Multiple Myeloma Patients with Acquired Resistance to Bortezomib or Lenalidomide
by: Shigeki Ito, et al.
Published: (2013-01-01)

Development of a Rapid and Sensitive HPLC Assay Method for Lenalidomide Capsules and Its Related Substances
by: L. Maheshwara Reddy, et al.
Published: (2012-01-01)

Topical transdermal administration of lenalidomide nanosuspensions-based hydrogels against melanoma: In vitro and in vivo studies
by: Mengdi Zhang, et al.
Published: (2025-06-01)

Epstein–Barr Virus Driven Hodgkin’s Lymphoma after a Short Course of Daratumumab Treatment for Relapsed Multiple Myeloma
by: Moeen Mohammadi-Oroujeh, et al.
Published: (2023-01-01)

The histone demethylase KDM5C enhances the sensitivity of acute myeloid leukemia cells to lenalidomide by stabilizing cereblon
by: Lu Zou, et al.
Published: (2025-01-01)

Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features
by: Abdullah M. Khan, et al.
Published: (2018-01-01)

Discovery of a Novel DYRK1A Mutation (c.524del) in Intellectual Development Disorder Autosomal Dominant 7 (MRD7): A Comprehensive Case Analysis
by: Fiona Whitaker, et al.
Published: (2024-01-01)

Combination effects of Pistachio hull and carfilzomib on NF-κB p65, MDR1, MRP1, and Caspase3 gene expression in breast cancer cell line
by: Zahra Mirzaei, et al.
Published: (2025-01-01)

Rare e14a3 (b3a3) BCR-ABL Fusion in Chronic Myeloid Leukemia in India: The Threats and Challenges in Monitoring Minimal Residual Disease (MRD)
by: Salil Vaniawala, et al.
Published: (2013-01-01)

Corrigendum to “Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features”
by: Abdullah M. Khan, et al.
Published: (2019-01-01)

Dual targeting PD-L1 and 4-1BB to overcome dendritic cell-mediated lenalidomide resistance in follicular lymphoma
by: Zhong Zheng, et al.
Published: (2025-01-01)

Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
by: Yin-Che Wang, et al.
Published: (2025-12-01)

Daratumumab treatment for kidney-involved light chain deposition disease prevents renal function progression: a case report with 3 years of follow-up and review of the literature
by: Xueying Chen, et al.
Published: (2025-01-01)

Food: God’s Gift to All People. Case Study from Croatia
by: Martina Ana Begić
Published: (2024-03-01)

Tissue tropism and clinical manifestation of chicken infectious bronchitis (review)
by: Ali Dandal Shebli, et al.
Published: (2018-04-01)

Engineering Judgment and Natural Circulation Calculations
by: J. C. Ferreri
Published: (2011-01-01)